Literature DB >> 7675968

Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing.

T Duka1, B Redemann, B Voet.   

Abstract

The effects of a single dose of scopolamine (0.5 mg) SC and of lorazepam (2.5 mg) PO were tested in two independent studies for their effects on performance in a psychometric battery which measured functions related to different stages of information processing. Attention and vigilance were measured by a continuous attention task and a vigilance task, respectively. Working memory and reasoning were evaluated by the rapid information processing and logical reasoning task; memory acquisition and storage were measured by pre- and post-drug immediate and delayed recall using visual material. The following pattern of effects was revealed; both scopolamine and lorazepam impaired performance in attentional and vigilance tasks as well as in the rapid information processing task significantly (P < 0.05) when compared with their own placebo; in the logical reasoning task lorazepam significantly prolonged the time required to solve a problem; scopolamine did not have any effect on this task. Scopolamine impaired performance in the immediate recall but left delayed recall unaffected; lorazepam impaired only delayed recall, immediate recall remaining unaffected. These data suggest that scopolamine at this dose impaired mostly attention and early stages of information processes; lorazepam at the dose tested impaired also the later acquisition and encoding aspects of memory.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675968     DOI: 10.1007/bf02246298

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Scopolamine and the control of attention in humans.

Authors:  M P Dunne; L R Hartley
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Models of memory dysfunctions.

Authors:  H Weingartner
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

4.  The effects of scopolamine on working memory in healthy young volunteers.

Authors:  J M Rusted; D M Warburton
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil.

Authors:  H V Curran; B Birch
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Human information-processing: some effects of methylphenidate, age, and scopolamine.

Authors:  E Callaway
Journal:  Biol Psychiatry       Date:  1984-05       Impact factor: 13.382

7.  Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood.

Authors:  H V Curran; F Schifano; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia.

Authors:  W W Beatty; N Butters; D S Janowsky
Journal:  Behav Neural Biol       Date:  1986-03

9.  Modelling dementia: effects of scopolamine on memory and attention.

Authors:  P Broks; G C Preston; M Traub; P Poppleton; C Ward; S M Stahl
Journal:  Neuropsychologia       Date:  1988       Impact factor: 3.139

10.  Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.

Authors:  T Sunderland; P N Tariot; R M Cohen; H Weingartner; E A Mueller; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1987-05
View more
  3 in total

1.  Effects of the amnesic drug lorazepam on complete and partial information retrieval and monitoring accuracy.

Authors:  M Izaute; E Bacon
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

2.  The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.

Authors:  T Duka; H Ott; A Rohloff; B Voet
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

3.  Human models as tools in the development of psychotropic drugs.

Authors:  Christian Gilles; Thérèse Schunck; Gilles Erb; Izzie Jacques Namer; Yann Hodé; Jean-François Nedelec; Peter Boeijinga; Remy Luthringer; Jean-Paul Mâcher
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.